Hengsai Bio Zhongshan R&D Center Opens

On the morning of October 28, the opening ceremony of Hengsai Bio Zhongshan R&D Center was held in Building 11 of Zhongshan Life Science Park. Relevant leaders of Zhongshan Market Supervision Administration, Science and Technology Finance Bureau of Cuiheng New District, Cuiheng Group, and representatives of investor, enterprise and park such as Hengsai Biologicals and Fuhui Equity Investment Management Co.

Cen Zhiyong, a member of the Party Group of Zhongshan Market Supervision Administration, congratulated Hengsai Biological on its opening. He said that Hengsai Biological is a leading R&D and production enterprise of dendritic cell vaccine (DC vaccine) in China, and its establishment is of great significance for promoting the development of biomedicine and health industry in Zhongshan. We hope that Hengsai Bio can adhere to the innovation drive, do a good job in R&D and production, and make greater contribution to driving the development of the industry and enhancing the level of national life and health.

Chao Hui, party committee member, director and deputy general manager of Cuiheng Group, said that Hengsai Bio is a demonstration project of Cuiheng Group which practiced investment to promote attraction and investment to promote production and landed in Cuiheng New District, and its DC vaccine products have shown a broad market space and wide application prospects. As an investor and park operator, Cuiheng Group will, as always, support the development of enterprises and help Hengsai Bio and other park enterprises to realize breakthroughs in the areas of capital increase and expansion of production, cost savings, efficiency improvement, and transformation of achievements, so as to promote the common prosperity of the park and enterprises.

Dr. Liu Huining, Founder, Chairman and CEO of Hengsai Biologicals, expressed her deep gratitude to all parties who have been supporting the development of the company. She said that the opening of Hengsai Bio Zhongshan R&D Center is an important milestone in the development of the company. Hengsai Biological will take this as a starting point to accelerate the development process in Guangdong, Hong Kong and Macao Greater Bay Area, and develop safer, long-lasting and universal DC vaccine products oriented by clinical needs and driven by scientific and technological innovation to lead the new wave of global cell therapy.

Founded in 2018, Hengsai Bio is a science and technology innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DC Vax platform, aiming to break down the technical barriers to industrialization, and develop safe and efficient, conveniently administered, high-quality DC vaccine products with independent intellectual property rights in the world's First-in-Class.

The Company's premiere pipeline KSD-101 has successfully completed dual reporting in China and the U.S., and has been granted an IND license by the U.S. Food and Drug Administration (FDA) for new drug clinical trials, the first original dendritic cell vaccine (DC Vaccine) product in China to receive an IND approval from the U.S. FDA. The company has now established stable cooperative relationships with a number of domestic and foreign research institutions and tertiary hospitals to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and efficacy of the DC vaccine.

The Zhongshan R&D Center of Hengsai Biologicals is one of the important layouts of Hengsai Biologicals' globalization strategy. Located on the 2nd floor of the 11th building of the Zhongshan Life Science Park, it occupies an area of about 1,000 square meters, and is equipped with one central laboratory and two R&D/pilot plants, which can meet the series of demands for the research and development, preparation, and testing of dendritic cell vaccines for the purpose of clinical research of IITs, and meanwhile meet the need for iterative upgrading of the company's globally leading Eco-Dc Vax At the same time, it can meet the needs of the iterative upgrading of the company's world-leading Eco-Dc Vax platform.